Johnson & Johnson Other Long-Term Assets 2010-2024 | JNJ
Johnson & Johnson other long-term assets from 2010 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Johnson & Johnson other long-term assets for the quarter ending September 30, 2024 were $10.921B, a 16.84% decline year-over-year.
- Johnson & Johnson other long-term assets for 2023 were $14.153B, a 53.64% increase from 2022.
- Johnson & Johnson other long-term assets for 2022 were $9.212B, a 9.83% decline from 2021.
- Johnson & Johnson other long-term assets for 2021 were $10.216B, a 55.68% increase from 2020.
Johnson & Johnson Annual Other Long-Term Assets
(Millions of US $) |
| 2023 |
$14,153 |
| 2022 |
$9,212 |
| 2021 |
$10,216 |
| 2020 |
$6,562 |
| 2019 |
$5,695 |
| 2018 |
$4,182 |
| 2017 |
$4,971 |
| 2016 |
$4,435 |
| 2015 |
$4,413 |
| 2014 |
$3,232 |
| 2013 |
$4,949 |
| 2012 |
$3,417 |
| 2011 |
$3,773 |
| 2010 |
$3,942 |
| 2009 |
$3,690 |
Johnson & Johnson Quarterly Other Long-Term Assets
(Millions of US $) |
| 2024-09-30 |
$10,921 |
| 2024-06-30 |
$10,544 |
| 2024-03-31 |
$14,125 |
| 2023-12-31 |
$14,153 |
| 2023-09-30 |
$13,133 |
| 2023-06-30 |
$10,078 |
| 2023-03-31 |
$9,567 |
| 2022-12-31 |
$9,212 |
| 2022-09-30 |
$8,625 |
| 2022-06-30 |
$9,435 |
| 2022-03-31 |
$9,939 |
| 2021-12-31 |
$10,216 |
| 2021-09-30 |
$6,870 |
| 2021-06-30 |
$7,172 |
| 2021-03-31 |
$6,538 |
| 2020-12-31 |
$6,562 |
| 2020-09-30 |
$6,131 |
| 2020-06-30 |
$5,782 |
| 2020-03-31 |
$5,042 |
| 2019-12-31 |
$5,695 |
| 2019-09-30 |
$5,307 |
| 2019-06-30 |
$5,430 |
| 2019-03-31 |
$5,159 |
| 2018-12-31 |
$4,182 |
| 2018-09-30 |
$4,465 |
| 2018-06-30 |
$4,421 |
| 2018-03-31 |
$4,518 |
| 2017-12-31 |
$4,971 |
| 2017-09-30 |
$5,021 |
| 2017-06-30 |
$5,273 |
| 2017-03-31 |
$4,690 |
| 2016-12-31 |
$4,435 |
| 2016-09-30 |
$4,245 |
| 2016-06-30 |
$3,977 |
| 2016-03-31 |
$4,163 |
| 2015-12-31 |
$4,413 |
| 2015-09-30 |
$3,804 |
| 2015-06-30 |
$3,855 |
| 2015-03-31 |
$3,605 |
| 2014-12-31 |
$3,232 |
| 2014-09-30 |
$5,033 |
| 2014-06-30 |
$6,435 |
| 2014-03-31 |
$6,459 |
| 2013-12-31 |
$4,949 |
| 2013-09-30 |
$2,715 |
| 2013-06-30 |
$2,477 |
| 2013-03-31 |
$3,723 |
| 2012-12-31 |
$3,417 |
| 2012-09-30 |
$3,521 |
| 2012-06-30 |
$3,891 |
| 2012-03-31 |
$3,956 |
| 2011-12-31 |
$3,773 |
| 2011-09-30 |
$3,905 |
| 2011-06-30 |
$4,193 |
| 2011-03-31 |
$3,705 |
| 2010-12-31 |
$3,942 |
| 2010-09-30 |
$3,552 |
| 2010-06-30 |
$3,200 |
| 2010-03-31 |
$3,622 |
| 2009-12-31 |
$3,690 |
| 2009-09-30 |
$3,581 |
| 2009-06-30 |
$2,682 |
| 2009-03-31 |
$2,589 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$368.366B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
